Still can't believe this one sneaks into the friday night attraction... thanks for the post CJ! : )
-----------------------------------------------
Many posts have gone to Dmitry Gabrilovich and Rolf Brekken, added Maria Karasarides to the list of AstraZeneca top oncologist leaders and many collaborating with Peregrine Pharmaceuticals... and just a bit more about Douglas Graham, MD Pdh Emory
Hopefully some leukemia news soon with much added hope with PS Targeting, and by the end of this post many will know 100% that Douglas Graham knows quite well that PS Targeting is required.
Nationwide search seeks out Douglas Graham and we continue to see some top docs around the country all surrounding themselves and embedded completely in PS Targeting....
all this must, eventually, point to some big things looming for Peregrine Pharmaceuticals. I only wished I was one of the ones that just found this gem of a stock at this very moment vs spending all this time up till now...
but all that time allowed me to build up to 100% confidence via all the puzzle pieces.
---------------------------------------------
Emory, Children's name new chief of Aflac Cancer & Blood Disorders Center
Woodruff Health Sciences Center | Sept. 30, 2015
Children's Healthcare of Atlanta and Emory University announce that after 15 years of dedicated service, William G. Woods, MD, has stepped down as director of the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta and chief of hematology/oncology/BMT in the Department of Pediatrics at Emory University. A nationwide search has identified Douglas Graham, MD, PhD, as the successor to this role. Dr. Graham joined Children's on August 17, 2015, and is working closely with Dr. Woods to ensure a successful transition.
"We are so thankful to Dr. Woods for his tremendous contributions to the Aflac Cancer Center," says Heather Davidson, vice president of hematology and oncology, Aflac Cancer Center. "Dr. Woods is a leader of great character, and everyone who has worked with him knows that our program would not be where it is today without his leadership. Under his tenure as director, the Aflac Cancer Center has grown in clinical and research faculty, grant funding, and research publications. His vision has led the Aflac Cancer Center to become one of the largest and most respected pediatric hematology/oncology programs in the country, now ranked by U.S. News & World Report among the top 10 pediatric cancer centers nationwide. He has truly built a legacy here."
Dr. Woods remains on faculty with the Aflac Cancer Center and Emory University. His new title is director emeritus.
"Dr. Graham brings to Children's a vision for the Aflac Cancer Center to enhance innovation and discovery across our core missions of clinical care, research and teaching," says Dr. Woods. "As we grow our program through new investment, recruitment and integration across our existing clinical and scientific expertise, Dr. Graham brings proven experience leading these missions. We are excited to have him join the team."
Dr. Graham is a member of the Senior Leadership Council of Winship Cancer Institute of Emory University. He will play a key role in helping to jointly recruit new oncology faculty with Winship.
The new director comes to the Aflac Cancer Center having previously served as professor of pediatrics and immunology at the University of Colorado, with clinical practice at Children's Hospital Colorado. While there, Dr. Graham led the Biology and Treatment of Childhood Cancer Research emphasis area. In this capacity, he directly oversaw all basic science, translational and clinical oncology research for the Center for Cancer and Blood Disorders at Children's Hospital Colorado.
Dr. Graham is a National Institutes of Health-funded investigator with an active laboratory focusing on developing novel therapeutics for pediatric cancer, recently validating MerTK as a novel cancer agent in leukemia, melanoma, non-small cell lung cancer and glioblastoma. He was the co-program leader of the Hematologic Malignancy Program at the University of Colorado, a National Cancer Institute-designated cancer center.
Digging deeper... how long has Douglas Graham known that PS Targeting is required ?? .... heck, even just back in March of 2015 this was posted 4 months after being published and Douglas Graham is one of the authors...
The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer
The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer
Douglas K. Graham, Deborah DeRyckere, Kurtis D. Davies & H. Shelton Earp
Affiliations Corresponding author
Nature Reviews Cancer 14, 769–785 (2014) doi:10.1038/nrc3847
Published online 24 November 2014
Abstract
Abstract• References• Author information• Supplementary information
The TYRO3, AXL (also known as UFO) and MERTK (TAM) family of receptor tyrosine kinases (RTKs) are aberrantly expressed in multiple haematological and epithelial malignancies. Rather than functioning as oncogenic drivers, their induction in tumour cells predominately promotes survival, chemoresistance and motility. The unique mode of maximal activation of this RTK family requires an extracellular lipid–protein complex. For example, the protein ligand, growth arrest-specific protein 6 (GAS6), binds to phosphatidylserine (PtdSer) that is externalized on apoptotic cell membranes, which activates MERTK on macrophages. This triggers engulfment of apoptotic material and subsequent anti-inflammatory macrophage polarization. In tumours, autocrine and paracrine ligands and apoptotic cells are abundant, which provide a survival signal to the tumour cell and favour an anti-inflammatory, immunosuppressive microenvironment. Thus, TAM kinase inhibition could stimulate antitumour immunity, reduce tumour cell survival, enhance chemosensitivity and diminish metastatic potential.
Affiliations
University of Colorado Comprehensive Cancer Center, Department of Pediatrics, School of Medicine, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado 80045, USA. Douglas K. Graham, Deborah DeRyckere & Kurtis D. Davies University of North Carolina Lineberger Comprehensive Cancer Center, Departments of Medicine and Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA. H. Shelton Earp
Competing interests statement
D.K.G. and H.S.E. are co-founders of Meryx, Inc., a company developing small-molecule MERTK kinase inhibitors. D.D. holds stock in Meryx, Inc. Corresponding author
Correspondence to:
H. Shelton Earp
Author details
Douglas K. Graham is Professor of Paediatrics at the School of Medicine, University of Colorado Denver, Anschutz Medical Campus, USA, and a paediatric oncologist at Children's Hospital Colorado. His work has focused on understanding the normal cellular functions of MERTK and AXL, as well as the potential for MERTK as a therapeutic target in multiple cancer types. Douglas K. Graham's homepage.
Deborah DeRyckere received her Ph.D. from the University of California, Berkeley, USA, and is currently Senior Research Associate in Douglas K. Graham's laboratory. Her work focuses on roles for MERTK in haematological malignancies, novel animal leukaemia models for the evaluation of therapeutic agents and the development of small-molecule and biological TYRO3, AXL and MERTK (TAM) receptor tyrosine kinase inhibitors for the treatment of cancer and other diseases.
Kurtis D. Davies is Research Instructor in Douglas K. Graham's laboratory. He received his Ph.D. in Pharmacology from the University of Colorado, Denver, USA, and went on to do two postdoctoral fellowships studying oncogenic kinases in various cancer types. His current research focuses on exploring the potential clinical utility of small-molecule MERTK and AXL inhibitors in non-small-cell lung cancer.
H. Shelton Earp, former Director of University of North Carolina Lineberger Cancer Center, USA, has studied cancer signalling for 40 years. His laboratory with his then M.D. Ph.D. student and long-term collaborator Douglas K. Graham identified MERTK. Ed Liu's laboratory next door in the Lineberger building identified AXL nearly simultaneously. With many collaborators from the University of North Carolina, the University of Colorado and other institutions, his laboratory has elucidated the physiological and neoplastic roles of MERTK and other tyrosine kinases.
How many more collaborations or older PS Targeting abstracts will be resurfacing ?? Every single researcher out there should want to be adding a bit of PS Targeting to validate for themselves and the lemons of the world can only point to the pps of PPHM for only so much longer.
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
AI
